These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 19752270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
    Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
    [Abstract] [Full Text] [Related]

  • 3. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.
    J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
    [Abstract] [Full Text] [Related]

  • 4. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.
    Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.
    Vaccine; 2008 Feb 13; 26(7):933-46. PubMed ID: 18226434
    [Abstract] [Full Text] [Related]

  • 5. Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
    Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.
    Vaccine; 2010 Dec 16; 29(2):289-303. PubMed ID: 21036130
    [Abstract] [Full Text] [Related]

  • 6. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
    Parker S, D'Angelo J, Buller RM, Smee DF, Lantto J, Nielsen H, Jensen A, Prichard M, George SL.
    Antiviral Res; 2021 Nov 16; 195():105179. PubMed ID: 34530009
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
    Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, Yang G, Jordan R, Hruby DE, Crance JM, Garin D, Andrei G, Snoeck R.
    Antivir Ther; 2008 Nov 16; 13(8):977-90. PubMed ID: 19195323
    [Abstract] [Full Text] [Related]

  • 10. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
    Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D.
    Antimicrob Agents Chemother; 2009 Jun 16; 53(6):2620-5. PubMed ID: 19349521
    [Abstract] [Full Text] [Related]

  • 11. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.
    Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, Maiti B, Meara I, Hruby DE.
    Expert Rev Anti Infect Ther; 2021 Mar 16; 19(3):331-344. PubMed ID: 32882158
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).
    Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, Clemmons CJ, Hudson P, Hruby DE.
    Antimicrob Agents Chemother; 2013 Dec 16; 57(12):6246-53. PubMed ID: 24100494
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nigericin is a potent inhibitor of the early stage of vaccinia virus replication.
    Myskiw C, Piper J, Huzarewich R, Booth TF, Cao J, He R.
    Antiviral Res; 2010 Dec 16; 88(3):304-10. PubMed ID: 20951746
    [Abstract] [Full Text] [Related]

  • 19. Molecule of the month. Tecovirimat.
    Drug News Perspect; 2008 Nov 16; 21(9):517. PubMed ID: 19180269
    [No Abstract] [Full Text] [Related]

  • 20. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.
    Baker RO, Bray M, Huggins JW.
    Antiviral Res; 2003 Jan 16; 57(1-2):13-23. PubMed ID: 12615299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.